0001209191-22-027196.txt : 20220504
0001209191-22-027196.hdr.sgml : 20220504
20220504174602
ACCESSION NUMBER: 0001209191-22-027196
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220502
FILED AS OF DATE: 20220504
DATE AS OF CHANGE: 20220504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huang Jane
CENTRAL INDEX KEY: 0001683913
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39527
FILM NUMBER: 22892978
MAIL ADDRESS:
STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES
STREET 2: 94 SOLARIS AVENUE
CITY: CAMANA BAY, GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prelude Therapeutics Inc
CENTRAL INDEX KEY: 0001678660
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811384762
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: (302) 547-3768
MAIL ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: Prelude Therapeutics Inc.
DATE OF NAME CHANGE: 20160630
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-02
0
0001678660
Prelude Therapeutics Inc
PRLD
0001683913
Huang Jane
C/O PRELUDE THERAPEUTICS INCORPORATED
200 POWDER MILL ROAD
WILMINGTON
DE
19801
0
1
0
0
President, CMO
Employee Stock Option (Right to Buy)
4.86
2022-05-02
4
A
0
460000
0.00
A
2032-04-30
Common Stock
460000
460000
D
Restricted Stock Unit
2022-05-02
4
A
0
150000
0.00
A
Common Stock
150000
150000
D
The stock option vests as to 25% of the total shares on April 4, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
The RSUs shall vest as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
/s/ Laurent Chardonnet, Attorney-in-Fact
2022-05-04